Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Xie Y, de Jager V, Chen R, Dodd L, Paripati P, Via L, Follmann D, Wang J, Lumbard K, Lahouar S, Malherbe S, Andrews J, Yu X, Goldfeder L, Cai Y, Arora K, Loxton A, Vanker N, Duvenhage M, Winter J, Song T, Walzl G, Diacon A, Barry C. Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis. Science Translational Medicine 2021, 13 PMID: 33536283, PMCID: PMC11135015, DOI: 10.1126/scitranslmed.abd7618.Peer-Reviewed Original ResearchConceptsPET/CT imagingPET/CTDrug treatmentCT imagingDrug combinationsD-glucose positron emission tomographyRecent phase 3 clinical trialsPhase 3 clinical trialsEarly bactericidal activity studyDrug combination activitySputum bacterial loadFirst-line chemotherapyPhase 3 trialHigh FDG uptakeLung lesion volumeActivity of pyrazinamideNew TB drugsPositron emission tomographyExperimental drug treatmentDrug regimensRadiological responseClinical outcomesFDG uptakeLung lesionsTB drugs